Abstract
The limitations of conventional treatment for non-Hodgkin's lymphoma (NHL) have led to intense investigations of biological therapies for this disease, including monoclonal antibodies. Conjugation of these antibodies with radionuclides results in additional cytotoxic activity with generally acceptable levels of toxicity. Numerous antibodies and radionuclides of widely varying properties are in clinical development. Given the likelihood that one or more radioimmunotherapeutic agents will soon be commercially available, there is a need for oncologists who treat patients with NHL to become more aware of the principles of radiation physics that underlie radioimmunotherapy and the interactions among radiolabeled antibodies, the tumor, and the host.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
